Metraipolis › archive › dc_34e613d4468f

Engineered metallic hybrid nanozyme for advanced inflammatory disease therapy — Europe PMC PMID:41362453

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41362453
DOI
10.1016/j.mtbio.2025.102572
License (as archived)
solo-consultazione
Archived
2026-11-08T10:40:44.217Z
SHA-256 of the archived text
37ebf927b143711ada5fb0e0a2ee28e552429cf508378cd339ededa4afb79450
Stable URL of this page
https://metraipolis.com/documento/dc_34e613d4468f

How to cite

Engineered metallic hybrid nanozyme for advanced inflammatory disease therapy — Europe PMC PMID:41362453 — Europe PMC (en), https://europepmc.org/article/MED/41362453 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_34e613d4468f (Metraipolis archive dc_34e613d4468f, sha256 37ebf927b143711ada5fb0e0a2ee28e552429cf508378cd339ededa4afb79450)
BibTeX
@misc{dc34e613d4468f,
  title = {Engineered metallic hybrid nanozyme for advanced inflammatory disease therapy — Europe PMC PMID:41362453},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41362453},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_34e613d4468f; sha256 37ebf927b143711ada5fb0e0a2ee28e552429cf508378cd339ededa4afb79450},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41362453. Agents can read the archived copy with the MCP tool read_document.